Commentary|Articles|June 5, 2026

CELMoDs and Bispecifics Break Through Across Lymphomas and Leukemias at EHA 2026

Fact checked by: Chris Ryan

Experts delineate the biggest presentations they are looking forward to being presented at the 2026 EHA Congress.

The upcoming 2026 EHA Congress marks a pivotal point for leukemia and lymphoma research, as many of this year’s top presentations are centered around how novel approaches like CELMoDS and bispecific antibodies can move standard-of-care regimens away from chemotherapy and toward treatments with reduced toxicity burdens.

Related to this article

Image Credit: © LELISAT - stock.adobe.com

September 3rd, 2026

Novel Therapies Are Poised to Answer Questions and Reinvigorate Hematologic Oncology at SOHO 2026

Experts break down SOHO 2026 and topics at the meeting that will shape hematologic oncology for the rest of the year.

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, breast cancer, head and neck cancer, pancreatic cancer, and follicular lymphoma.

August 23rd, 2026

Five Under 5: Top Oncology Videos for the Week of 8/16

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, breast cancer, head and neck cancer, pancreatic cancer, and follicular lymphoma.

Brain Cancer | Image Credit: © iDoPixBox - stock.adobe.com

September 4th, 2026

Brachytherapy and Minimally Invasive Surgical Techniques Signal the Future of Brain Cancer Management

Brain cancer experts explain the current wave of surgical advances and advocate for team-based, multidisciplinary strategies to individualize patient care.

September 4th, 2026

Novel Analysis Reveals Millions of Life-Years Saved by Blood Cancer Treatments

A new life-years-saved methodology found blood cancer treatments saved million years of life since 1949, with future gains reliant on funding and access.

September 3rd, 2026

AML Research Centers Around the Optimization of Available Combinations

Uma Borate, MBBS, MS, discusses data for different azacitidine and venetoclax schedules from the Beat AML master clinical trial.

Prostate Cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

September 2nd, 2026

New Biomarker-Driven Regimens Prompt Debate Over Treatment Intensification in Advanced Prostate Cancer

Faculty convened at an OncLive Scientific Interchange and Workshop to weigh how new regimens should reshape sequencing in prostate cancer.

Image by Ashling Wahner & MJH Life Sciences Using AI

September 1st, 2026

Comprehensive RNA-Based Testing and Selective Next-Generation TKIs Are Reshaping Frontline ROS1+ NSCLC Care

During a recent OncLive Peer Exchange, panelists discussed testing strategies, updated data, and treatment sequencing in ROS1+ NSCLC.

August 31st, 2026

MAPKeeper-301 Aims to Confirm the Efficacy of Atebimetinib in Metastatic Pancreatic Cancer

The MAPKeeper-301 trial is evaluating frontline atebimetinib plus chemotherapy vs standard chemotherapy in metastatic pancreatic ductal adenocarcinoma.